IRIS

Adjuvant Low-Dose Interleukin-2 (IL-2) Plus Interferon-a (IFN-a) in Operable Renal Cell Carcinoma (RCC): A Phase III, Randomized, Multicentre Trial of the Italian Oncology Group for Clinical Research (GOIRC) (vol 37, pg 440, 2014) / Passalacqua, R; Caminiti, C; Buti, S. - In: JOURNAL OF IMMUNOTHERAPY. - ISSN 1524-9557. - 38:5(2014), pp. 216-216.

Adjuvant Low-Dose Interleukin-2 (IL-2) Plus Interferon-a (IFN-a) in Operable Renal Cell Carcinoma (RCC): A Phase III, Randomized, Multicentre Trial of the Italian Oncology Group for Clinical Research (GOIRC) (vol 37, pg 440, 2014)

Buti S
2014-01-01
2014
Adjuvant Low-Dose Interleukin-2 (IL-2) Plus Interferon-a (IFN-a) in Operable Renal Cell Carcinoma (RCC): A Phase III, Randomized, Multicentre Trial of the Italian Oncology Group for Clinical Research (GOIRC) (vol 37, pg 440, 2014) / Passalacqua, R; Caminiti, C; Buti, S. - In: JOURNAL OF IMMUNOTHERAPY. - ISSN 1524-9557. - 38:5(2014), pp. 216-216.
1.1 Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2906857
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact